Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension.Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n = 382, 45.3 ± 4.6 years) and postmenopausal women (post-MPW; n = 991, 60.9 ± 8.2 years).Baseline clinic systolic BP was not different (pre-MPW; 152.9 ± 15.2 vs. post-MPW; 152.8 ± 13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7 ± 9.4 vs. post-MPW; 91.9 ± 9.4 mm Hg, P <0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7 ± 17.7/-14.2 ± 11.3 vs. post-MPW; -25.7 ± 16.3/-13.1 ± 10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3 ± 17.9/-23.1 ± 15.8 vs. post-MPW; -20.4 ± 17.3/-20.2 ± 19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW.Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.
From the Department of Internal Medicine (S-YK, S-JJ), Jeju National University School of Medicine, Jeju; Division of Cardiology (M-SS), Department of Internal Medicine, Gachon University Gil Medical Center, Incheon; Department of Preventive Medicine (CK), Yonsei University College of Medicine; Division of Cardiology (EJC), Department of Internal Medicine, St. Paul's Hospital, Catholic University of Korea; Division of Cardiology (K-CS), Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine; Cardiology Division (S-MK), Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul; Division of Cardiology (D-SK), Paik Hospital, Inje University College of Medicine, Busan; Division of Cardiology (SHL), Wonju Severance Christian Hospital, Wonju Medical College, Yonsei University, Wonju; Department of Internal Medicine (K-KH), Chungbuk National University College of Medicine, Cheongju; and Division of Cardiology (JBP), Department of Internal Medicine, Cheil General Hospital, Dankook University College of Medicine, Seoul, South Korea.
Song-Yi
SY
Kim
Seung-Jae
SJ
Joo
Mi-Seung
MS
Shin
Changsoo
C
Kim
Eun Joo
EJ
Cho
Ki-Chul
KC
Sung
Seok-Min
SM
Kang
Dong-Soo
DS
Kim
Seung Hwan
SH
Lee
Kyung-Kuk
KK
Hwang
Jeong Bae
JB
Park
D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory / Q000706:statistics & numerical data; D005260:Female; D006785:Hospitals, University; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D017698:Postmenopause; D011446:Prospective Studies; D011674:Pulse; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D056910:Republic of Korea; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D011743:Pyrimidines; D013777:Tetrazoles; C558933:fimasartan